As filed with the Securities and Exchange Commission on March 16, 2022
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Satsuma Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
2834 |
|
81-3039831 |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(650) 410-3200
(Address, including zip code, and telephone number, including area code, of Registrants principal executive offices)
2019 Incentive Award Plan,
2019 Employee Stock Purchase Plan
(Full Title of the Plan)
John Kollins
President
and Chief Executive Officer
Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
(650) 410-3200
(Name, address, including zip code, and telephone number, including area code, of agent for service)
|
|
|
Copies to: |
|
|
Brian J. Cuneo
Latham & Watkins LLP
140 Scott Drive Menlo
Park, California 94025 Telephone: (650) 328-4600 |
|
Tom ONeil
Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard, Suite 221
South San Francisco, CA 94080
Telephone: (650) 410-3200 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐